You could be reading the full-text of this article now if you...

If you have access to this article through your institution,
you can view this article in

Management of Severe Allergic Conjunctivitis With Topical Cyclosporin A 0.05% Eyedrops

Ozcan, Altan A MD; Ersoz, T Reha MD; Dulger, Erol MD

Cornea:
doi: 10.1097/ICO.0b013e31812dfab3
Clinical Science
Abstract

Purpose: To evaluate the efficacy of topical cyclosporin A 0.05% in the management of severe allergic conjunctivitis.

Methods: Seven patients with severe allergic conjunctivitis who were not responding to topical steroids, antihistamines, and mast cell stabilizers were given topical cyclosporin A 0.05%. All patients had an active disease when they were included in the study. Signs and symptoms were recorded before and after treatment.

Results: Seven patients, 6 boys and 1 girl, 6-14 years old, 6 with vernal keratoconjunctivitis and 1 with atopic keratoconjunctivitis, were enrolled in the study. Treatment with topical cyclosporin A 0.05% decreased the severity of symptoms and clinical signs significantly after 6 months (P < 0.05, Wilcoxon signed rank test). In addition, the need for steroids was reduced or even stopped. The patients experienced no side effects during the follow-up periods (mean, 14.0 ± 2.1 months; range, 8-18 months).

Conclusions: Topical cyclosporin A is an effective treatment in the management of severe allergic conjunctivitis with a benefit as a steroid-sparing agent.

Author Information

From the Department of Ophthalmology, Çukurova University, Faculty of Medicine, Adana, Turkey.

Received for publication December 1, 2006; revision received May 11, 2007; accepted May 16, 2007.

The authors state that they have no proprietary interest in the products named in this article.

Reprints: Altan A. Ozcan, Cukurova University Medical Faculty, Department of Ophthalmology, 01330 Balcali, Adana, Turkey (e-mail: altanoz@cu.edu.tr).

Copyright © 2007 Wolters Kluwer Health, Inc. All rights reserved.